



PATENT  
ATTORNEY DOCKET NO.: 053529-5007-01-US  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**MAIL STOP PATENT APPLICATION**

U.S. Patent and Trademark Office  
2011 South Clark Place  
Crystal Plaza Two, Lobby Room 1B03  
Arlington, VA 22202



**TRANSMITTAL FOR A NEWLY EXECUTED ORIGINAL APPLICATION  
UNDER 37 C.F.R. § 1.53(b)**

This is a request for filing a patent application under 37 C.F.R. § 1.53(b) for:

Inventor(s):

Berkley     **LYNCH**  
Karl        **NOCKA**  
Bruno      **FUKS**

FOR:     METHODS FOR THE IDENTIFICATION OF AGENTS FOR THE  
         TREATMENT OF SEIZURES, NEUROLOGICAL DISEASES,  
         ENDOCRINOPATHIES AND HORMONAL DISEASES

1.     This is a new ☒ **Utility**   ☐ **Design**   ☐ **Plant** patent application.
2.     The papers enclosed to obtain a filing date are as follows:  
         78 Pages of Specification including  
              20     Pages of Claims  
              01     Page(s) of Abstract  
         24 Sheets of Figures (Figs. 1-22)
3.     Combined Declaration and Power of Attorney  
         ☐     Enclosed and is executed by all inventors.  
         ☒     Not Enclosed.  
         This application is being filed under the provisions of 37 C.F.R. § 1.53(f).  
         Applicant(s) await notification from the Patent and Trademark Office of the  
         time set for filing the Declaration and paying the filing fees.

## 4. Language

☒ English☐ Non-English

This application is being filed in accordance with 37 C.F.R. § 1.52(d) and § 608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

## 5. Assignment

☐ An assignment of the invention to \_\_\_\_\_ and a PTO Form-1595, Recordation Form Cover Sheet, are enclosed.

☒ An assignment will be filed at a later date.

## 6. Priority based on provisional application(s) - 35 U.S.C. § 119(e)

☒ Priority of the following provisional application(s) is claimed:

| Application No. | Filed              |
|-----------------|--------------------|
| 60/430,372      | December 3, 2002   |
| 60/506,764      | September 30, 2003 |

## 7. Fee Calculation (37 C.F.R. § 1.16)

| CLAIMS FOR FEE CALCULATION   |   |       |              |                  |                 |   |
|--|---|-------|--------------|------------------|-----------------|---|
|  | Number<br>Filed After<br>Preliminary<br>Amendment |       | Number Extra | Present<br>Extra | at Rate of      | Basic Fee<br>Utility \$770.00<br><br>Total Fees |
| Total Claims<br>(37 C.F.R. §1.16(c))                                       |   | minus | 20           | 0                | x \$18.00 each= | \$ 0.00   |
| Independent Claims<br>(37 C.F.R. §1.16(b))                                 |   | minus | 3            | 0                | x \$86 each=    | \$ 0.00   |
| <input type="checkbox"/> First presentation of Multiple Dependent Claim(s) |   |       |              |                  | 290.00          | \$ 00.00  |
| Reduction by 1/2 for filing by a small entity                              |   |       |              |                  |                 | \$ 0.00   |
| TOTAL FILING FEE =   |   |       |              |                  |                 | \$ 0.00   |

8. Fee Payment

- ☒ Not Enclosed. **NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**

This application is being filed under the provisions of 37 C.F.R. § 1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

9. ☒ **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

10. Additional papers enclosed:

- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement
- ☐ Form PTO-1449, \_\_\_\_\_ references included
- ☐ Declaration of Biological Deposit
- ☒ Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

**Please accord this application an application number and filing date.**

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**



Michael S. Tuscan

Reg. No. 43,210

Dated: **December 2, 2003**

**Customer No. 09629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Avenue  
Washington, D.C. 20004  
(202) 739-3000